Results 31 to 40 of about 8,187 (238)

Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol [PDF]

open access: yesCurrent Issues in Molecular Biology
In recent years, novel antimicrobials have been developed to counter the emergence of antimicrobial resistance and provide effective therapeutic options against multidrug-resistant (MDR) Gram-negative bacilli (GNB).
G. Bianco   +11 more
semanticscholar   +2 more sources

Cefiderocol Resistance in Klebsiella pneumoniae Is Linked to SHV Extended-Spectrum β-Lactamase Activities and Functional Loss of the Outer Membrane Porin OmpK35

open access: yesMicrobiology Spectrum, 2023
Klebsiella pneumoniae AR 0047 from the CDC and FDA Antibiotic Resistance Isolate Bank is resistant to cefiderocol, a siderophore-conjugated cephalosporin.
Sun Hee Moon, En Huang
doaj   +1 more source

Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei [PDF]

open access: yes, 2023
Cefiderocol is a siderophore cephalosporin designed mainly for treatment of infections caused by β-lactam and multidrug-resistant Gram-negative bacteria.
Bart J., Currie   +11 more
core   +1 more source

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019

open access: yesMicrobiology Spectrum, 2022
Cefiderocol was evaluated by broth microdilution versus 1,050 highly antimicrobial-resistant Pseudomonas aeruginosa clinical isolates from the CANWARD study (2007 to 2019).
James A. Karlowsky   +9 more
doaj   +1 more source

The solution to drug resistance of Gram-negative bacteria – Cefiderocol [PDF]

open access: yes, 2023
Introduction: A major public health problem is the emergence of anti-gram-negative antimicrobial resistance worldwide. Cefiderocol is a new agent targeting Gram-negative bacteria, including strains with resistance to carbapenems.
Jastrzębska, Ilona   +4 more
core   +3 more sources

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program

open access: yesMicrobiology Spectrum, 2022
Cefiderocol is a siderophore-conjugated cephalosporin with broad activity against Gram-negative (GN) bacteria, including carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa, Acinetobacter spp., and Stenotrophomonas maltophilia ...
Dee Shortridge   +3 more
doaj   +1 more source

Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations

open access: yesIDCases, 2020
Cefiderocol is a novel siderophore cephalosporin antibacterial with activity against carbapenem-resistant Gram-negative bacteria including Pseudomonas aeruginosa.
Wesley D. Kufel   +5 more
doaj   +1 more source

In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014–2018

open access: yesJournal of Global Antimicrobial Resistance, 2021
: Objectives: The prevalence of Gram-negative bacteria (GNB) demonstrating extensive, multiple antimicrobial resistance is increasing in England, leaving few treatment choices.
Vanya Gant   +4 more
doaj   +1 more source

Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway

open access: yesJournal of Global Antimicrobial Resistance, 2023
: Here we report the in vivo development of cefiderocol resistance within 11 days after therapy initiation in a critically ill patient with bloodstream infection, infection of peri-anal fistula, and pneumonia caused by a VIM-2 harbouring, carbapenem ...
Luise Brakert   +8 more
doaj   +1 more source

In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany

open access: yesJournal of Global Antimicrobial Resistance, 2022
: Objectives: Widespread antimicrobial resistance in Gram-negative bacteria (GNB), particularly carbapenem resistance, represents a major clinical challenge.
Philipp Thelen   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy